A Long-term Follow-up Study of Patients With MPS IIIB From Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)

Trial Information
Status: Terminated
Location: See all (3) locations...
Intervention Type: Biological
Study Type: Observational

This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 years post-treatment).

Am I eligible for this trial?
Participation Requirements
Healthy Volunteers:

• Participants that have completed a prior clinical trial involving the administration of ABO-101

• Parent(s)/legal guardian(s) of participant willing and able to complete the informed consent process and comply with study procedures and visit schedule

Where is this trial taking place?
United States
Nationwide Children's Hospital
Other Locations
Armand-Trousseau Hospital
University Hospital Hamburg-Eppendorf
When is this trial taking place?
Start Date: October 28, 2020
Completion Date: April 7, 2022
How many participants will be in this trial?
Target number of participants: 1
What treatment is being studied in this trial?
Participants from prior interventional trials involving the administration of ABO-101.

This content was sourced from clinicaltrials.gov

A Phase 0 Study of Infigratinib in Recurrent High-Grade Glioma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK Triggered Expansion Cohort
Who is this study for:Patients with recurrent high-grade glioma scheduled for resection
Start Date:July 21, 2020
Study Drug:Infigratinib
Study Type:Drug
Phase: Early Phase 1
Care Ecosystem: Navigating Patients and Families Through Stages of Care, Extension Trial
Status:Active, not recruiting
Start Date:March 20, 2015
Study Type:Behavioral
Phase: Not Applicable